Treats inhalational anthrax due to Bacillus anthracis. Sold as Raxibacumab. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Raxibacumab (sold as Raxibacumab), first approved Dec 14, 2012, with 1 new use approved and 0 published complete response letters.
| Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxInfections, Bacterial · Emergent BioSolutions | — | Not yet recruiting | Mar 17, 2026 |
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioInfections, Bacterial · Emergent BioSolutions | Phase 4 | Not yet recruiting | Jun 30, 2014 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 14, 2012 | RaxibacumabBLA 125349 · New molecular entity | Human Genome Sciences Inc. | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
